Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q4 Loss of $0.33

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q4 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $20.9 million.

For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Cisco rating cut at HSBC as analyst sees a lack of catalysts
• Reading (RDI) Tops Q2 EPS by 4c